BridgeBio Pharma (BBIO) has announced a $300 million royalty financing deal for its drug acoramidis, known as BEYONTTRA in Europe, aimed at strengthening its financial position ahead of significant launches and late-stage programs. This announcement has generated considerable discussion on X, reflecting investor interest in the company’s strategic efforts to fund its pipeline amid a competitive biotech landscape.
In the past six months, BridgeBio insiders have conducted 37 trades—only sales, totaling approximately $303 million, indicating a negative sentiment among insiders regarding the stock. During the most recent quarter, 182 institutional investors increased their positions in BBIO, while 108 decreased theirs, with notable moves including Kohberg Kravis Roberts & Co. removing 6 million shares.
